Juan R. Cubillos-Ruiz

Juan R. Cubillos-Ruiz

Auto-generated profile, based on publicly available information

Juan R. Cubillos-Ruiz

Weill Cornell Medicine

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
XCXi Chen
Xi Chen
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz

1 February 2017 in Cell
Verified
Journal Article
Closed access
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
SBSarah E. Bettigole
Sarah E. Bettigole
LGLaurie H. Glimcher
Laurie H. Glimcher

10 October 2018 in Nature
Verified
Journal Article
Open access
PDF file
MSMinkyung Song
Minkyung Song
TSTito A. Sandoval
Tito A. Sandoval
CCChang-Suk Chae
Chang-Suk Chae
SCSahil Chopra
Sahil Chopra
CTChen Tan
Chen Tan
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
Tumours evade immune control by creating hostile microenvironments that perturb T cell metabolism and effector function1,2,3,4. However, it remains unclear how intra-tumoral T cells integrate and interpret metabolic stress signals. Here we report that ovarian cancer—an aggressive malignancy that is refractory to standard treatments and current immunotherapies5,6,7,8—induces endoplasmic reticulum stress and activates the IRE1α–XBP1 arm of the unfolded protein response9,10 in T cells to control their mitochondrial respiration and anti-tumour function. In T cells isolated from specimens collected from patients with ovarian cancer, upregulation of XBP1 was associated with decreased infiltration of T cells into tumours and with reduced IFNG mRNA expression. Malignant ascites fluid obtained from patients with ovarian cancer inhibited glucose uptake and caused N-linked protein glycosylation defects in T cells, which triggered IRE1α–XBP1 activation that suppressed mitochondrial activity and IFNγ production. Mechanistically, induction of XBP1 regulated the abundance of glutamine carriers and thus limited the influx of glutamine that is necessary to sustain mitochondrial respiration in T cells under glucose-deprived conditions. Restoring N-linked protein glycosylation, abrogating IRE1α–XBP1 activation or enforcing expression of glutamine transporters enhanced mitochondrial respiration in human T cells exposed to ovarian cancer ascites. XBP1-deficient T cells in the metastatic ovarian cancer milieu exhibited global transcriptional reprogramming and improved effector capacity. Accordingly, mice that bear ovarian cancer and lack XBP1 selectively in T cells demonstrate superior anti-tumour immunity, delayed malignant progression and increased overall survival. Controlling endoplasmic reticulum stress or targeting IRE1α–XBP1 signalling may help to restore the metabolic fitness and anti-tumour capacity of T cells in cancer hosts.

1 August 2019 in Trends in Immunology
Verified
Journal Article
Closed access
PGPaolo Giovanelli
Paolo Giovanelli
TSTito A. Sandoval
Tito A. Sandoval
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz

21 August 2020 in Science
Verified
Journal Article
Closed access
KPKyle Kristopher Payne
Kyle Kristopher Payne
JMJessica A. Mine
Jessica A. Mine
SBSubir Biswas
Subir Biswas
RCRicardo A. Chaurio
Ricardo A. Chaurio
APAlfredo Perales-Puchalt
Alfredo Perales-Puchalt
JCJose R Conejo-Garcia
Jose R Conejo-Garcia
BTN3A1 governs antitumor responses: T lymphocytes are immune cells that can be activated through their gamma delta (γδ) or alpha beta (αβ) receptors. Both T cell types are found in human cancers, but current immunotherapies do not harness their coordinated antitumor activity. Payne et al. found that BTN3A1 and BTN2A1, two members of the butyrophilin family of proteins, partner to activate the most abundant subset of γδ T cells in peripheral blood. Antibodies targeting BTN3A1 redirect γδ T cells to attack cancer cells while also increasing the activity of tumor-specific αβ T cells. Thus, the killing of established tumors by different T cell subsets can be achieved through BTN3A1 targeting and may provide new strategies for cancer immunotherapy. Science , this issue p. 942

8 July 2022 in Trends in Cancer
Verified
Journal Article
Closed access
CSCamilla Salvagno
Camilla Salvagno
JMJessica K. Mandula
Jessica K. Mandula
PRPaulo C. Rodriguez
Paulo C. Rodriguez
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz